Inventage Lab announced on the 26th that it was selected as the lead company for the national research and development project 'Development of AI-based digital automation process system for customized lipid nanoparticles for nucleic acid therapeutics' supported by the Ministry of Trade, Industry and Energy.
This project will be conducted over 4 years and 9 months with a scale of approximately 8.5 billion won, centered around Inventage Lab, Terna Therapeutics, and AM Square as a consortium. The goal is to build an AI-based LNP formulation design and manufacturing process automation system and to develop mRNA-based obesity treatment preclinical trials using this system.
In a preliminary study, administering mRNA LNP for obesity treatment to a high-fat diet animal model resulted in approximately 10% body weight loss and significant improvement in liver fat accumulation within 7 days. This demonstrated the potential of mRNA obesity treatment and the scalability of platform technology.
Inventage Lab will lead the construction of an AI-integrated digital twin system and process optimization by utilizing a microfluidics-based LNP formulation development and production platform and a GMP-compliant manufacturing infrastructure. Terna Therapeutics will be responsible for mRNA engineering and specialized LNP formulation development, while AM Square will be responsible for AI prediction models and process digital twin implementation. The three organizations will cooperate in building a next-generation therapeutic CDMO platform ecosystem ranging from formulation design, process automation, non-clinical development, and production.
mRNA technology has proven its potential and value worldwide through the development of the COVID-19 vaccine, and is currently expanding into various treatment fields such as cancer, rare diseases, and metabolic diseases. Inventage Lab is strengthening the competitiveness of its domestic LNP platform by applying AI-based process optimization technology and establishing a GMP-level mass production system. In particular, it expects a strategic advantage in precision formulation design and process efficiency in conquering the obesity treatment market.
“We aim to innovate the LNP manufacturing process by converging AI and microfluidics,” said Inventage Lab CEO Joohee Kim. “This project will contribute to improving the speed and efficiency of new drug development as well as strengthening global competitiveness in the mRNA therapeutics field.”
- See more related articles
You must be logged in to post a comment.